![]() |
|
|
|
|
|
|
|
|
![]() |
|
ALPHAGAN® P ophthalmic solution is approved for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Important Safety Information ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% should not be used in patients receiving monoamine oxidase (MAO) inhibitor therapy. Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, ocular redness, and itching. Adverse events occurring in approximately 5% to 9% included: burning sensation, increased ocular lymph nodules, increased ocular pressure, ocular allergic reaction, dry mouth, and blurred vision. Please click here for full Prescribing Information. 1. MedlinePlus® Medical Encyclopedia. US National Library of Medicine and the National Institutes of Health Web sites. Available at: http://www.nlm.nih.gov/medlineplus/encyclopedia.html. Accessed June 7, 2006. 2. MedlinePlus® Medical Dictionary. US National Library of Medicine and the National Institutes of Health Web sites. Available at: http://www.nlm.nih.gov/medlineplus/mplusdictionary.html. Accessed June 7, 2006. 3. Stedman's Medical Dictionary. 27th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:405. 4. Glaucoma surgery page. Glaucoma Research Foundation website. Available at: http://www.glaucoma.org/treating/surgery.html. Accessed July 14, 2006. 5. Ocular Hypertension page. American Optometric Association Web site. Available at: http://www.aoa.org/x772.xml. Accessed June 7, 2006. 6. Glaucoma Resource Guide page. National Eye Institute Web site. Available at: http://www.nei.nih.gov/health/glaucoma/glaucoma_facts.asp. Accessed June 7, 2006. 7. Don't Lose Sight of Glaucoma page. National Eye Institute Web site. Available at: http://www.nei.nih.gov/health/glaucoma/glaucoma_risk.asp. Accessed June 7, 2006. |



